1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Surgical operations during the COVID-19 outbreak: Should elective surgeries be suspended?

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The current outbreak of coronavirus disease (COVID-19) which causes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread since the end of 2019 from China. After the index case, increasing number of cases are being reported in many countries across the world [1,2]. The mortality rate of SARS-CoV-2 was 3.6% [3.5–3.7] in China and is 1.5% [1.2–1.7] in outside of China [3]. Safety of health workers and patients who are admitted to hospitals and health centers are of potential concern during SARS-CoV-2 outbreak [4]. The decision whether to suspend elective surgical operations during the current epidemic is a challenging topic in many centers. It is obvious that patients who need emergent surgical operations and trauma victims should be hospitalized and managed during the SARS-CoV-2 outbreak [5]. These patients may have symptomatic COVID-19 infection or be silent transmitters. In symptomatic cases, routine diagnostic and therapeutic measures should be applied and isolation should be conducted. In addition, it seems that patients who were in close contact with SARS-CoV-2 patients during the 14 days before their admission should be tested for COVID-19 [6]. The test can be performed either by chest computed tomography (CT) or real-time polymerase chain reaction (RT-PCR). The decision to suspend or cancel elective surgical operations should not only be made on the risk of COVID-19 spread. The surgical team should consider risks of cancer, vascular disease, organ failure and progression of the disease [7]. All reconstructive and cosmetic surgeries can be postponed to a time when COVID-19 crisis calms down. All surgeries of benign tumors in head and neck, breast, thoracic cavities and abdomen can be suspended. However, the benign condition should be proved by pathological report. The decision on suspending surgeries for malignancies should be assessed by the surgical team. Thyroid and parathyroid malignancies and other head and neck malignant tumors should not be suspended. Breast malignancies should be reviewed by the surgical teams. Neoadjuvant treatments should not be delayed. In addition, surgical operations should not be delayed in women who have completed their neoadjuvant courses. Gastrointestinal (GI) malignancies also should be reviewed by the surgical team and neoadjuvant treatments should be initiated based on evidence-based guidelines. Delaying surgical resection should be assessed considering the risk of COVID-19 spread, progression of the tumor and the risk of metastasis. Palliative procedures for GI obstructions should also not be suspended [8]. Many orthopedic and neurosurgical operations can be suspended. Urologic operations can also be suspended; however, renal and bladder cancers should be evaluated precisely. Access surgery for patients on dialysis is a potential concern. Patients with newly established end stage renal disease who require emergent dialysis should undergo catheter dialysis placement. Arteriovenous fistula (AVF) and arteriovenous graft (AVG) procedures can be postponed unless the risk of catheter failure or infection exists. Failed and infected catheters also should be managed by catheter irrigation or exchange. Thrombosed preexisting AVFs and AVGs should be managed by thrombectomy followed by venoplasty or other procedures based on evidence-based indications. Ruptured aortic and other arterial aneurysms should be operated emergently. However, non-ruptured aneurysms should be postponed unless the risk of rupture overweighs current risk of COVID-19 spread. Almost all venous and lymphatic procedures can be suspended. However, severe deep venous thromboembolisms (DVT) with phlegmasia may require emergent or urgent operations. Surgeries for aortoiliac occlusive disease and peripheral arterial disease can be postponed unless a progressive arterial ulcer necessitates an urgent operation to restore the arterial flow. Medical treatments should be kept in mind. It seems that endovascular techniques with local or spinal anesthesia may have lower risk because intubation and ventilation management are potential concerns during the current COVID-19 outbreak. However, elective endovascular procedures should be postponed [9]. Liver transplantation should also be limited to urgent cases in the epidemic areas. However, a more liberal allocation for patients outside the epidemic areas is recommended. All recipients should be screened to avoid transplantation in COVID-19 positive individuals. Post-transplant surveillance is also mandatory [10]. In conclusion, elective surgical operations should be suspended in current COVID-19 outbreak in epidemic areas unless the risks of the disease impose a potential risk, morbidity or organ failure in the patient. Ethical approval N/A. Sources of funding None. Author contribution The commentary has been written by SZ. Research registration number N/A. Guarantor SZ. Data statement This manuscript does not contain data. Provenance and peer review Not Commissioned, internally reviewed. Declaration of competing interest The author does not have any conflicts of interests.

          Related collections

          Most cited references7

          • Record: found
          • Abstract: found
          • Article: found

          World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

          An unprecedented outbreak of pneumonia of unknown aetiology in Wuhan City, Hubei province in China emerged in December 2019. A novel coronavirus was identified as the causative agent and was subsequently termed COVID-19 by the World Health Organization (WHO). Considered a relative of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), COVID-19 is caused by a betacoronavirus named SARS-CoV-2 that affects the lower respiratory tract and manifests as pneumonia in humans. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with 90,870 laboratory-confirmed cases and over 3,000 deaths worldwide. In response to this global outbreak, we summarise the current state of knowledge surrounding COVID-19.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Real estimates of mortality following COVID-19 infection

            As of March 1, 2020, 79 968 patients in China and 7169 outside of China had tested positive for coronavirus disease 2019 (COVID-19). 1 Among Chinese patients, 2873 deaths had occurred, equivalent to a mortality rate of 3·6% (95% CI 3·5–3·7), while 104 deaths from COVID-19 had been reported outside of China (1·5% [1·2–1·7]). However, these mortality rate estimates are based on the number of deaths relative to the number of confirmed cases of infection, which is not representative of the actual death rate; patients who die on any given day were infected much earlier, and thus the denominator of the mortality rate should be the total number of patients infected at the same time as those who died. Notably, the full denominator remains unknown because asymptomatic cases or patients with very mild symptoms might not be tested and will not be identified. Such cases therefore cannot be included in the estimation of actual mortality rates, since actual estimates pertain to clinically apparent COVID-19 cases. The maximum incubation period is assumed to be up to 14 days, 2 whereas the median time from onset of symptoms to intensive care unit (ICU) admission is around 10 days.3, 4 Recently, WHO reported that the time between symptom onset and death ranged from about 2 weeks to 8 weeks. 5 We re-estimated mortality rates by dividing the number of deaths on a given day by the number of patients with confirmed COVID-19 infection 14 days before. On this basis, using WHO data on the cumulative number of deaths to March 1, 2020, mortality rates would be 5·6% (95% CI 5·4–5·8) for China and 15·2% (12·5–17·9) outside of China. Global mortality rates over time using a 14-day delay estimate are shown in the figure , with a curve that levels off to a rate of 5·7% (5·5–5·9), converging with the current WHO estimates. Estimates will increase if a longer delay between onset of illness and death is considered. A recent time-delay adjusted estimation indicates that mortality rate of COVID-19 could be as high as 20% in Wuhan, the epicentre of the outbreak. 6 These findings show that the current figures might underestimate the potential threat of COVID-19 in symptomatic patients. Figure Global COVID-19 mortality rates (Feb 11 to March 1, 2020) Current WHO mortality estimates (total deaths divided by total confirmed cases), and mortality rates calculated by dividing the total number of deaths by the total number of confirmed cases 14 days previously.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic

              Coronavirus disease 2019 (COVID-19) has placed an enormous strain on the health care systems of the nations where it has spread widely, with specific implications of the disease on practice in the catheterization laboratory. These implications include how we might modify practice for standard cardiac patients, those who are suspected to have COVID-19, and those with COVID-19 who have either unrelated cardiac conditions or cardiac manifestations of the disease. It merits emphasis that this is a dynamic situation and one for which there are limited data. In addition, local conditions may vary considerably. The purpose of this joint statement from the American College of Cardiology (ACC) Interventional Council and the Society for Cardiovascular Angiography and Interventions (SCAI) is to discuss issues facing catheterization laboratory personnel during this time. Although this is new territory for most of us, it should be noted that the Middle East respiratory syndrome and severe acute respiratory syndrome epidemics within the past 2 decades did provide some limited information on the effects of highly contagious and morbid respiratory diseases on the catheterization laboratory (1). Patient Selection for the Catheterization Laboratory Elective patients Many institutions in the United States have already placed a moratorium on elective procedures within the catheterization laboratory in an effort to preserve resources and avoid exposure of patients to the hospital environment, where COVID-19 may be more prevalent. This certainly seems prudent in locales where the disease is highly prevalent. Under any circumstance, to preserve hospital bed capacity, it would seem reasonable to avoid elective procedures on patients with significant comorbidities or in whom the expected length of stay is >1 to 2 days (or anticipated to require the intensive care unit). In addition, the definition of truly elective requires clinical judgment, because in some cases deferral of patients may have independent deleterious effects. However, examples of procedures to defer include: 1) percutaneous coronary intervention for stable ischemic heart disease; 2) endovascular intervention for iliofemoral disease in patients with claudication; and 3) patent foramen ovale closure. Case decisions should be individualized, taking into account the risk for COVID-19 exposure versus the risk for delay in diagnosis or therapy. Patients with ST-segment elevation myocardial infarction A recent report from China outlines a protocol that relies on rapid nucleic acid testing and reliance on fibrinolytic therapy (2). This is a controversial subject, especially in the United States, where primary percutaneous coronary intervention is the routine for patients with ST-segment elevation myocardial infarction (STEMI). Furthermore, it is complicated by the fact that access to rapid testing is limited. However, in a patient with known COVID-19 and STEMI, the balance of staff exposure and patient benefit will need to be weighed carefully. Fibrinolysis can be considered an option for a relatively stable patient with STEMI with active COVID-19. In patients with active COVID-19 in whom primary percutaneous coronary intervention is to be performed, appropriate personal protective equipment (PPE) should be worn, including gown, gloves, goggles (or shields), and an N95 mask, especially given the limited ability to take a history from such patients as well as the potential for clinical deterioration in those with STEMI. The use of powered air-purifying respirator systems may also be reasonable, especially for patients who may be vomiting (e.g., inferior STEMI) or those who may require cardiopulmonary resuscitation (CPR) and/or intubation. Importantly, the vast number of catheterization laboratories have either normal or positive ventilation systems and are not designed for infection isolation. Therefore, catheterization laboratories will require a terminal clean following the procedure, leading to delays for subsequent procedures. Patients with NON–ST-segment elevation myocardial infarction For most patients with non-ST-segment elevation myocardial infarction (NSTEMI) and suspected COVID-19, timing should allow for diagnostic testing for COVID-19 prior to cardiac catheterization and for a more informed decision regarding infection control. Rapid discharge of patients with primary NSTEMI following revascularization will likely be important in terms of maximizing bed availability and reducing patient exposure within the hospital. Follow-up through telehealth venues could be satisfactory in most cases. It has been suggested that in appropriately selected cases of patients with known COVID-19 and NSTEMI (e.g., particularly for those with type 2 myocardial infarction), conservative therapy may be sufficient on the basis of patient risk. It is important to note that recent reports suggest that acute cardiac injury is present in about 7% of patients with COVID-19 and may represent either type 2 myocardial infarction or myocarditis (3). All of these factors need to be taken into account when weighing risks and benefits vis-à-vis infection control. Efforts should be made to try to differentiate between these type 2 myocardial infarctions and “primary” acute coronary syndromes, with consideration of deferral of invasive management in the former, especially if the patient is hemodynamically stable. Unstable patients with NSTEMI whose instability is due to the acute coronary syndrome (rather than other factors) may be considered under the STEMI rubric outlined earlier. Patients requiring intubation, suctioning, or CPR Intubation, suction, and active CPR likely result in aerosolization of respiratory secretions increasing likelihood of exposure to personnel. Patients who are already intubated pose less of a transmission risk to staff members given that their ventilation is managed through a closed circuit. Patients with COVID-19 or suspected COVID-19 requiring intubation should be intubated prior to arrival to the catheterization laboratory. Furthermore, the threshold to consider intubation in a patient with borderline respiratory status may need to be lowered to avoid emergent intubation in the catheterization laboratory. Some institutions have suggested using a high-efficiency particulate air filter between tube and bag if staff members are bagging an intubated patient, as bag ventilation can increase aerosolization. Other considerations are to use closed-circuit bilevel positive airway pressure machines if intubation not available. Close coordination with critical care, infectious disease, and anesthesia teams in airway management will be critical to avoid spread of infection. Resource Allocation and Protection of the Team of Health Care Workers Catheterization laboratory time Consideration should be given to laboratory downsizing case volumes (e.g., deferral of elective cases) and or shift-based allocation of staff members and physicians needed to operate the laboratory in anticipation of likely disruptions to staffing. Despite measures to reduce exposure, staff shortages should be anticipated on the basis of both the possibility of infected, exposed, or quarantined staff members as well as the derivative impact on staff members due to school closings, which will put a strain on home, dependent, and child care resources. Specific consideration to subspecialty care teams may be required, with separation of persons with overlapping skill sets (e.g., avoidance of 2 structural heart interventionalists being in the same care area simultaneously). Given the infectious risk of transporting patients from wards to the catheterization laboratory, some procedures routinely done in the catheterization laboratory should be considered for bedside performance. Examples include pulmonary artery catheter placement, pericardiocentesis, and intra-aortic balloon pump insertion. As mentioned earlier, the vast majority of catheterization laboratories have either normal or positive ventilation systems and are not designed for infection isolation. Given the need for terminal cleaning following procedures on patients with suspected or known COVID-19, these cases should be done at the end of the working day if possible. For known COVID-19-positive patients, restriction of cases to a dedicated laboratory may be of value. Protection of Health Care Workers and PPE All catheterization laboratory personnel should be fit-tested for N95 masks and be well versed in the proper techniques for doffing and donning PPE, including eye protection. There may be situations in which the use of powered air-purifying respirator systems is advised. All catheterization laboratory directors and managers should work closely with their institutional infection control groups to ensure adequate availability and training in the use of this equipment. Ideally for patients with known COVID-19 or suspected COVID-19 who are required to come to the catheterization laboratory, patients should wear surgical masks, and all members of the catheterization laboratory team should don PPE (preferably for aerosolized precautions given the risk of emergent intubation, suctioning, and CPR). In addition to the known shortage of N95 masks, there are emerging reports of shortages of gowns, gloves, and regular surgical masks. This supports the deferral of elective cases and a reduction in the number of people who scrub into procedures. This is particularly relevant for teaching institutions, at which multiple physicians often scrub into cases. Vendor access and use of PPE should be limited to those cases only when absolutely essential. A Need for Ongoing Information As the medical community gains more experience dealing with the various issues raised by the COVID-19 pandemic, it will be important to have an ability to exchange experiences and best practices. Already, social media has provided a venue for some excellent discussions and insight from practitioners at institutions experiencing the effects of the pandemic. As the pandemic progresses, we will need to create avenues for reporting and collation of data and then methods for rapidly dispersing that information in order to better care for our patients and to protect health care workers.
                Bookmark

                Author and article information

                Contributors
                Journal
                Int J Surg
                Int J Surg
                International Journal of Surgery (London, England)
                IJS Publishing Group Ltd. Published by Elsevier Ltd.
                1743-9191
                1743-9159
                14 April 2020
                June 2020
                14 April 2020
                : 78
                : 5-6
                Affiliations
                [1]Department of Surgery, Shohada-Tajrish Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
                [2]Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
                Author notes
                []Correaponding author. Department of Surgery, Shohada-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. s.zarrintan@ 123456yahoo.com
                Article
                S1743-9191(20)30292-2
                10.1016/j.ijsu.2020.04.005
                7194740
                32302745
                dd7c805c-197a-4094-a318-8e44adf3089c
                © 2020 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 30 March 2020
                : 8 April 2020
                Categories
                Article

                Surgery
                corona-virus,covid-19,pandemic
                Surgery
                corona-virus, covid-19, pandemic

                Comments

                Comment on this article